Harm in a medical and regulatory context refers to injury or an adverse impact on trial participants, patients, or public health. The term is used in clinical trials, pharmacovigilance, and benefit–risk assessment and includes both specific adverse events and longer-term negative consequences that may arise from an intervention, misuse, or systemic factors.
Conceptual classification
“Harm” is broader than a single adverse event: it may include physical, psychological, social, or economic consequences. In studies, harm is often captured via safety endpoints, for example through adverse events and serious adverse events. In practice, it is important to distinguish correlation from causality: not every event occurring during treatment is caused by the treatment, but it may still require documentation in the safety dataset.
Harm must also be distinguished from “risk”: risk describes the combination of the probability of occurrence and the severity of a potential harm, whereas harm refers to the harm itself. This distinction is central to risk management plans and to communication in informed consent documents. Misunderstandings often arise when risks are reported only as frequencies without explaining the clinical context of the possible consequences.
Harm in clinical trials: ethics and patient protection
Protection from harm is a core principle of the Declaration of Helsinki and Good Clinical Practice. Before a study starts, ethics committees and authorities assess whether the expected benefit–risk balance is acceptable. This includes, among other things, appropriate inclusion and exclusion criteria, monitoring strategies, safety reporting pathways, and clear emergency care at the trial sites.
Another key component is informed consent: participants must be informed in understandable language about possible risks and burdens. In EU trials, this is closely linked to EU Regulation 536/2014 (Clinical Trials Regulation), which structures transparency, safeguards, and reporting obligations. Also practically relevant are processes for re-consent when new risks become known or the protocol changes.
Safety reporting and regulatory consequences
When harm occurs as an adverse event, defined processes for capture, assessment, and reporting apply. Particularly relevant are SUSARs, which must be reported as suspected unexpected serious adverse reactions within strict timelines. Consistent safety management not only reduces harm, but also prevents inspection findings, e.g., due to late reporting, incomplete narratives, or inconsistent coding.
From a sponsor’s perspective, harm is also closely linked to “stopping rules”: for certain safety patterns, a Data Safety Monitoring Board may recommend a study pause, protocol amendments, or termination. For CROs, this means that monitoring, data management, and medical monitoring must be closely aligned so that signals are detected early. Predefined thresholds, regular signal reviews, and a clear responsibility matrix between the sponsor and service providers also play a role.
Harm minimisation: risk management and quality measures
Harm can be reduced through preventive measures. These include risk-based monitoring, robust standard operating procedures, training for trial sites, and an effective deviation and CAPA system. Typical causes of avoidable harm include medication errors, unclear dosing instructions, insufficient follow-up of laboratory values, or delayed responses to warning signals.
Data quality also plays a role: if safety data are captured late or incorrectly, indirect harm arises because decisions are made on an incomplete basis. Audits and inspections therefore assess whether processes and systems are suitable to identify and address harm systematically. A proven approach is to test safety processes already during study start-up, e.g., using training cases, and to clearly define interfaces to central systems (EDC, safety database).
In addition, organisational factors can influence harm, such as unclear responsibilities between sponsor, CRO, and trial site, or insufficient escalation logic for safety issues. In practice, clear communication pathways, regular safety meetings, and consistent documentation of assessments have proven effective to ensure that decisions remain traceable in the event of an audit or inspection.
Benefit–risk assessment beyond the study context
After approval, harm continues to be monitored as part of pharmacovigilance. New safety information may lead to updates to the product information, risk minimisation measures, or, in rare cases, changes to the marketing authorisation. In the EU, this is supported, among other things, through EMA structures (e.g., PRAC). For patient care, it is also relevant that real-world evidence can contribute to the assessment of rare or long-term harms.
For communication, this means that risks and potential harm must be explained in a target-group-appropriate manner, e.g., to physicians, patients, and authorities. In benefit–risk assessment, harm aspects are not considered in isolation, but evaluated in the context of disease severity, available alternatives, and the target population. Particularly in serious diseases, a higher potential for harm may be acceptable if the benefit is compelling and appropriate risk minimisation is implemented. At the same time, it must be documented that measures for early detection and management of adverse reactions are realistically feasible.
FAQ
How does harm differ from an “adverse event”?
An adverse event is a documented occurrence within a defined time period. Harm describes the actual injury or negative impact and may extend across multiple events, subsequent complications, or indirect effects.
Who assesses in a study whether harm is acceptable?
Before the study starts, the ethics committee and the competent authority review the benefit–risk balance. During the study, the sponsor, investigator, and, where applicable, a Data Safety Monitoring Board continuously assess safety data and decide on adjustments.
How can harm be reduced in study practice?
Through good participant information, clear SOPs, training, close safety surveillance, rapid reporting of relevant cases, and consistent actions in response to deviations (CAPA).
Regulatory References (Selection)
- ICH E6(R3) Good Clinical Practice (patient protection, safety processes)
- EU Regulation 536/2014 (Clinical Trials Regulation, protection and reporting requirements)
- Declaration of Helsinki (ethical core principles)